Showing results (61-70 of 270) with videos related to

Sort By:
Pageof 27
Nuclear Medicine Communications|April 15, 2017
Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patientsLaura Evangelista, Anna R Cervino, Silvia Michieletto, et al.
NPJ Breast Cancer|February 4, 2023
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trialMaria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, et al.
Breast Cancer Research and Treatment|April 3, 2010
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancerValentina Guarneri, David Miles, Nicholas Robert, et al.
Frontiers in Oncology|December 19, 2018
Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological SanctuaryTommaso Giarratano, Federica Miglietta, Carlo A Giorgi, et al.
Breast (Edinburgh, Scotland)|July 30, 2025
Impact of germline BRCA1/2 status on outcomes for patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a systematic review and meta-analysisMichele Bottosso, Christian Zurlo, Federica Miglietta, et al.
Cancer Treatment Reviews|September 10, 2022
Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?Federica Miglietta, Luca Visani, Sabrina Marini, et al.
Frontiers in Oncology|July 24, 2024
Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysisGiulia Pasello, Alberto Pavan, Mattia De Nuzzo, et al.
Future Oncology (London, England)|July 23, 2025
Management of trastuzumab deruxtecan-related adverse events in breast cancer: Italian expert panel recommendationsGiampaolo Bianchini, Alessandra Fabi, Valentina Guarneri, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2025
Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohortDaniela Scattolin, Anne-Marie C Dingemans, Alessandro Dal Maso, et al.
International Journal of Cancer|August 24, 2012
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent yearsLaura Cortesi, Luigi Marcheselli, Valentina Guarneri, et al.
Pageof 27